NeuroVive enters strategic collaboration with University of Pennsylvania

Lund, Sweden, 12 January 2016 – NeuroVive Pharmaceutical AB (publ), the
mitochondrial medicine company, announces that it has entered into a research
partnership with University of Pennsylvania to enhance NeuroVive’s traumatic
brain injury (TBI) research and development program.
The research partnership will focus on an important unsolved problem in the
medical field: nerve cell protection following moderate to severe brain trauma.
The agreement between University of Pennsylvania and NeuroVive represents the
expanding footprint beyond Europe into the US and will further advance the
company’s understanding of and presence in the US market.

The research collaboration is to provide more data on NeuroVive’s drug for the
treatment of TBI, NeuroSTAT®, and will provide the company with additional
preclinical data to support the regulatory filings for the TBI indication.
NeuroVive will, via this partnership, get access to highly experienced
scientists at University of Pennsylvania and the Children’s Hospital of
Philadelphia whom have world-renown expertise in the area of TBI research.

“The collaboration with Drs. Susan Margulies and Todd Kilbaugh at the University
of Pennsylvania and the Children’s Hospital of Philadelphia is a very positive
step for NeuroVive. The company is progressing its TBI research program through
the CHIC trial and these next steps together with UPENN will provide us with
supporting evidence which will complement the ongoing CHIC trial evaluating the
safety of NeuroSTAT® in TBI. We hope to initiate the first studies during the
first quarter of 2016” said Eskil Elmér, Chief Scientific Officer of NeuroVive.

“Our team of researchers and scientists at the University of Pennsylvania and
the Children’s Hospital of Philadelphia are enthusiastic about the opportunity
to leverage our investigations at the forefront of TBI research to identify TBI
treatments. This partnership with NeuroVive is designed as a pre-clinical
translational bridge between potential therapies and clinical trials, to explore
treatments for TBI where there are few options for patients” commented Dr. Susan
S. Margulies, Professor in Bioengineering and Neurosurgery at the University of
Pennsylvania.

About TBI
Traumatic brain injury (TBI) is brain damage that occurs after an external
trauma to the head, where nerve cells receive immediate damage. The injury
deteriorates for several days after the accident, often leading to a significant
impact on the overall injurious effect. TBI afflicts approximately 1.7 million
Americans annually with more than 52,000 associated deaths and 275,000
hospitalisations.* Both direct and indirect costs associated with TBI are
estimated at more than $60 billion with a high number of patients left with
moderate to severe disabilities requiring intensive care and support. It is
hoped that better treatments for TBI, such as NeuroSTAT®, will lead to increased
survival and greatly improved outcomes in terms of the ability of patients to
function normally following moderate to severe TBI.
About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a mitochondrial medicine company committed
to the discovery and development of highly targeted candidates that preserve
mitochondrial integrity and function in areas of significant therapeutic need.
NeuroVive’s business approach is driven by value-adding partnerships with
mitochondrial research institutions and commercial partners across the globe.
NeuroVive’s portfolio consists of two clinical projects in acute kidney injury
(AKI) and traumatic brain injury (TBI), one candidate in preclinical development
and two drug discovery platforms. NeuroSTAT® has orphan drug status in Europe
and in the US for treatment of moderate to severe traumatic brain injury and is
currently being evaluated in a Phase II study. CicloMulsion® is being evaluated
in an on-going Phase II study, CiPRICS, in acute kidney injury during major
surgery. NeuroVive’s shares are listed on NASDAQ Stockholm, Sweden.
Disclaimer
This release may contain forward-looking statements that can be identified by
words such as “recommends,” “indicating,” “risk,” “recommended,” “believe,”
“could,” “commitment,” “will,” “implications,” “supports,” “thought,”
“designed,” “growing,” “continues,” or similar terms, or by expressed or implied
discussions regarding potential marketing approvals for NeuroSTAT®, or regarding
potential future revenues from NeuroSTAT®. You should not place undue reliance
on these statements. Such forward-looking statements are based on the current
beliefs and expectations of management regarding future events, and are subject
to significant known and unknown risks and uncertainties. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that NeuroSTAT® will be
submitted or approved for sale in any market, or at any particular time. Nor can
there be any guarantee that NeuroSTAT® will be commercially successful in the
future. In particular, management’s expectations regarding NeuroSTAT® could be
affected by, among other things, the uncertainties inherent in research and
development, including unexpected clinical trial results and additional analysis
of existing clinical data; unexpected regulatory actions or delays or government
regulation generally; the company’s ability to obtain or maintain proprietary
intellectual property protection; general economic and industry conditions;
global trends toward health care cost containment, including ongoing pricing
pressures; unexpected manufacturing issues, and other risks and factors.

For investor relations and media questions, please contact:
Johannes Nebel, Laika Consulting, Tel: +46 (0)735 81 71 68 or ir@neurovive.com
It is also possible to arrange an interview with NeuroVive’s CEO Jan Nilsson at
the above contacts.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on the 12 January 2016, at 08.30 CET.

----------------------------------------------------------------------

*U.S. Centers for Disease Control and Prevention (CDC). National Center for
Injury Prevention and Control. Injury prevention and control: traumatic brain
injury. For more information about TBI, please visit
http://www.cdc.gov/TraumaticBrainInjury/data/index.html